创伤患者按体重调整依诺肝素剂量预防静脉血栓栓塞症:系统评价与荟萃分析
该研究为系统评价与荟萃分析,纳入4项比较成人创伤患者(18岁及以上)标准剂量与按体重调整依诺肝素预防静脉血栓栓塞症的队列研究。主要结局为抗Xa因子水平达到预防范围,按体重调整组达到预防范围的比值比为5.85(95%CI 3.02-11.30,p<0.00001),亚预防水平风险降低(RR 3.97,95%CI 3.02-5.22,p<0.00001);标准剂量组超治疗水平风险降低(RR 0.23,95%CI 0.11-0.50,p=0.0002)。两组出血事件风险差异为-0.00(95%CI -0.02至0.01,p=0.55),静脉血栓栓塞症发生率风险差异为0.01(95%CI -0.02至0.03,p=0.64),均无统计学差异。作者认为需进一步研究明确该获益是否转化为静脉血栓栓塞症预防改善及发生率降低。
要点
- 在成人创伤患者中,按体重调整依诺肝素预防剂量与抗Xa因子达到预防范围的比值比升高相关(OR 5.85,95%CI 3.02-11.30,p<0.00001)。
- 按体重调整组亚预防抗Xa因子水平风险降低(RR 3.97,95%CI 3.02-5.22,p<0.00001)。
- 标准剂量组超治疗抗Xa因子水平风险降低(RR 0.23,95%CI 0.11-0.50,p=0.0002)。
- 两组出血事件风险差异为-0.00(95%CI -0.02至0.01,p=0.55),静脉血栓栓塞症发生率风险差异为0.01(95%CI -0.02至0.03,p=0.64),均无统计学差异。
- 作者认为需进一步研究明确按体重调整剂量是否转化为静脉血栓栓塞症预防改善及发生率降低。
适用人群与场景
- 成人创伤患者,年龄18岁及以上,比较标准剂量与按体重调整依诺肝素预防静脉血栓栓塞症的研究人群。
研究设计与关键结果
- 研究类型为系统评价与荟萃分析,纳入4项队列研究,人群为成人创伤患者(18岁及以上),干预为按体重调整依诺肝素预防剂量,对照为标准剂量。
- 主要结局:按体重调整组抗Xa因子达到预防范围的比值比升高(OR 5.85,95%CI 3.02-11.30,p<0.00001)。
- 次要结局:按体重调整组亚预防抗Xa因子水平风险降低(RR 3.97,95%CI 3.02-5.22,p<0.00001);标准剂量组超治疗抗Xa因子水平风险降低(RR 0.23,95%CI 0.11-0.50,p=0.0002)。
- 出血事件风险差异为-0.00(95%CI -0.02至0.01,p=0.55),静脉血栓栓塞症发生率风险差异为0.01(95%CI -0.02至0.03,p=0.64),均无统计学差异。
证据类型、等级与局限
- 证据类型为系统评价与荟萃分析,证据等级为Level III。
- 作者指出需进一步研究明确按体重调整剂量是否转化为静脉血栓栓塞症预防改善及发生率降低。
对床旁实践的改变
- 在成人创伤患者中,按体重调整依诺肝素预防剂量与抗Xa因子达到预防范围的比值比升高相关,但静脉血栓栓塞症发生率与出血风险无显著差异;作者认为需进一步研究明确其临床获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Trauma patients are at high risk of developing venous thromboembolism (VTE), and standard dosing enoxaparin regimens may be inadequate for prophylaxis. This meta-analysis was performed to clarify the efficacy of alternative dosing regimens for VTE prophylaxis in this high-risk group. The objective of this systematic review was to review the evidence regarding weight-based dosing of enoxaparin for VTE prophylaxis in trauma patients.
METHODS: A systematic database search was undertaken for studies comparing standard versus weight-based dosing of enoxaparin for VTE prophylaxis in adult trauma patients, 18 years or older. The primary outcome was the achievement of anti-factor Xa (AFXa) levels within the prophylactic range. Secondary outcomes included subprophylactic AFXa levels, supraprophylactic AFXa levels, VTE incidence, and bleeding events. Meta-analysis was conducted using both fixed- and random-effects models, and presented as odds ratios, risk ratios (RRs), and risk differences (RDs) with 95% confidence intervals (CIs).
RESULTS: Four cohort studies were eligible for inclusion. Compared with standard dosing, weight-based enoxaparin prophylaxis dosing was associated with increased odds of prophylactic AFXa levels (odds ratio, 5.85; 95% CI, 3.02-11.30; p < 0.00001) and reduced risk of subprophylactic AFXa levels (RR, 3.97; 95% CI, 3.02-5.22; p < 0.00001). Standard dosing was associated with a reduced risk of supratherapeutic AFXa levels (RR, 0.23; 95% CI, 0.11-0.50; p = 0.0002), but this was not associated with a difference in risk of bleeding events (RD, -0.00; 95% CI, -0.02 to 0.01; p = 0.55). There was no statistical difference in incidence VTE between the two groups (RD, 0.01; 95% CI, -0.02 to 0.03; p = 0.64).
CONCLUSION: Compared with standard dosing, weight-based enoxaparin dosing regimens are associated with increased odds of prophylactic range AFXa levels. Further investigation is required to determine if this translates into improved VTE prophylaxis and reduced VTE incidence.
LEVEL OF EVIDENCE: Systematic Review and Meta-Analysis; Level III.
参考来源
- Ebeid A, Cole E, Stallwood-Hall C, et al. The efficacy of weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients: A systematic review and meta-analysis. J Trauma Acute Care Surg. 2022. PMID: 35583986. doi:10.1097/TA.0000000000003707
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。